Abstract
ABSTRACTBackgroundThe novel South London and Maudsley Brain Health Clinic (SLaM BHC) leverages advances in remote consultations and biomarkers to provide a timely, cost-efficient and accurate diagnosis in mild cognitive impairment (MCI).AimsTo describe the organisation, patient cohort, and acceptability of the remote diagnostic and interventional procedures.MethodWe describe the recruitment, consultation setup, the clinical and biomarker program, and the two online group interventions for cognitive wellbeing and lifestyle change. We evaluate the acceptability of the remote consultations, lumbar puncture (LP), saliva genotyping and remote cognitive and functional assessments.ResultsWe present the results of the first 68 (mean age 73, 55% female, 43% ethnic minority) of 146 patients who enrolled for full remote clinical, cognitive, genetic, cerebrospinal fluid, and neuroimaging phenotyping. 86% were very satisfied/ satisfied with the remote service. 67% consented to LP and 95% of those were very satisfied, all having no significant complications. 93% found taking saliva genotyping very easy/easy and 93% found the cognitive assessments instructions clear. 98% were satisfied with the cognitive wellbeing groups and 90% of goals were achieved in the lifestyle intervention group.ConclusionsThe SLaM BHC provides a highly acceptable and safe clinical model for remote assessments and lumbar punctures in a representative, ethnically diverse population. This allows early and accurate diagnosis of Alzheimer’s, differentiation from other MCI causes and targets modifiable risk factors. This is crucial for future disease modification, ensuring equitable access to research, and provides precise, timely and cost-efficient diagnoses in UK mental health services.
Publisher
Cold Spring Harbor Laboratory
Reference32 articles.
1. Dementia incidence trend in England and Wales, 2002–19, and projection for dementia burden to 2040: analysis of data from the English Longitudinal Study of Ageing;The Lancet Public Health,2023
2. Mild Cognitive Impairment: The Manchester consensus;Age and Ageing,2021
3. van Dyck CH , Swanson CJ , Aisen P , Bateman RJ , Chen C , Gee M , et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2022 Nov 29;NEJMoa2212948.
4. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
5. Donanemab in Early Symptomatic Alzheimer Disease